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Abstract 36 
Tissue products are susceptible to microbial contamination from different sources, which may 37 
cause disease transmission upon transplantation. Terminal sterilization using gamma 38 
radiation, electron-beam, and ethylene oxide protocols are well-established and accepted, 39 
however, such methods have known disadvantages associated with compromised tissue 40 
integrity, functionality, safety, complex logistics, availability, and cost. Non-thermal (cold) 41 
atmospheric pressure plasma (CAP) is an emerging technology that has several biomedical 42 
applications including sterilization of tissues, and the potential to surpass current terminal 43 
sterilization techniques. This review discusses the limitations of conventional terminal 44 
sterilization technologies for biological materials, and highlights the benefits of utilizing CAP. 45 
 46 
  47 
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1 INTRODUCTION 48 
Tissues and biological transplant materials (TBTM), including bone, soft tissues, and other 49 
biologically derived biomaterials should be sterilized to prevent transmission of 50 
microorganisms to the recipient. TBTM typically possess a natural microbial 51 
load/bioburden1 or acquire one during collection and processing. If not eliminated, this has 52 
the potential to cause an infection leading to transplant failure, and further harm to the patient. 53 
Prevention of disease transmission is of primary concern to TBTM manufacturers and the 54 
regulatory authorities. 55 
Sterilization is the confident and reproducible elimination of all forms of life. Terminal 56 
sterilization is considered the final step in the manufacturing process of a sterile product in its 57 
final packaging.[1] Terminal sterilization is used in the processing of TBTM to provide 58 
sterility assurance and is generally mandated by national regulatory authorities.[2] Terminal 59 
sterilization is required when: TBTM are processed in non-aseptic conditions; are not treated 60 
by any other form of decontamination; use non-sterile consumables; or are stored in 61 
conditions that do not prevent microbial growth. There is no ideal sterilization process for all 62 
biological materials. Each strategy faces advantages and disadvantages, requiring numerous 63 
considerations when choosing sterilization methods, including: 64 
• Material compatibility. 65 
• Reliability against bacterial spores, endotoxins, and viruses. 66 
• Effect on production process. 67 
• Expense. 68 
Although terminal sterilization destroys contaminating microbial agents, the process also 69 
devitalizes the cells of the tissue. As a result, terminal sterilization is unsuitable for TBTM 70 
that are intended to include viable and healthy donor cells. Non-viable TBTM are routinely 71 
used for diverse applications ranging from homotopic, long-term transplants such as bone 72 
grafts[3, 4]; to short-term heterotopic transplants, such as amniotic membrane (AM) which 73 
can be used as an ocular surface bandage.[5, 6] In these situations, terminal sterilization is 74 
appropriate. Preservation of the original structure and function of a tissue, both mechanically 75 
and biochemically is essential. However, most sterilization methods can substantially damage 76 
biological materials. 77 
4 
 
Classical terminal sterilization methods such as ionizing radiation and ethylene oxide (EtO) 78 
have limitations including TBTM degradation, prolonged sterilization cycles, cost, logistical 79 
difficulties and inefficiency against viruses, prions, and endotoxins. Thus, an effective 80 
sterilization procedure capable of maintaining a balance between sterilization efficacy, cost, 81 
and retention of TBTM structural and functional properties is required for elimination of such 82 
resistant contaminants. 83 
Trials of non-thermal (cold) atmospheric pressure plasma (CAP) sterilization methods on 84 
viable cells and tissues are promising.[7-11] Although CAP is potentially restricted to the 85 
sterilization of thinner TBTM, further optimization could deliver reduced cost, time, logistics, 86 
and damage. In contrast with conventional sterilization methods, literature has reported that 87 
CAP possesses the ability to eradicate all resistant contaminants such as viruses, prions, 88 
endotoxins, and biofilm from the treated surfaces.[12, 13] 89 
This review compares the limitations of classic terminal sterilization of TBTM including 90 
gamma (γ), electron beam (e-beam) and EtO, and addresses the possibility of implementing 91 
CAP technologies with a particular focus on the sterilization of non-viable AM. 92 
 93 
2 CHALLENGES OF TBTM MANUFACTURING AND RISK OF 94 
CONTAMINATION 95 
Tissue processing protocols vary, depending upon tissue structure and composition and the 96 
intended application, which determines how well the structural and functional properties of 97 
the native tissue need to be maintained. Processing of TBTM may include dissection, 98 
intensive, and prolonged washing steps to remove blood and cellular components to diminish 99 
the presence of antigens and disease, defatting, demineralization, and decellularization. 100 
TBTM may be preserved dry, or in hydrated form, at ambient or cold storage conditions; they 101 
may be aseptically prepared, high level decontaminated, or terminally sterilized.[14] 102 
Optimized manufacturing procedures are crucial for the quality and safety of the final product. 103 
There are specified international regulatory directives set to ensure prevention of risk from 104 
communicable disease transmission agents during procurement, processing, preservation, 105 
storage, and use of TBTM (Directive 2004/23/EC).[15] 106 
In the UK, under Human Tissue Authority (HTA) regulations, viable and non-viable tissues 107 
can be prepared without terminal sterilization. However, such procedures require stringent 108 
preparation and in-process monitoring compared with terminally sterilized tissues. Long-term 109 
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storage of cryopreserved tissue requires specialist storage at −135 °C and with specific 110 
cryoprotectants such as dimethyl sulfoxide or glycerol; whereas non-viable, dehydrated 111 
(freeze-, heat-, or vacuum-dried) tissue can be vacuum-packed and stored at ambient 112 
temperature for up to five years.[16] 113 
In the US, transplantable materials such as bone, tendon, ligament, dura mater, heart valves, 114 
skin, cornea, and AM are designated as “human cell, tissue, cellular or tissue-based products” 115 
(HCT/P) by the US Food and Drug Administration (FDA), with the stipulation that it is 116 
minimally manipulated as regulated under section 361 of the Public Health Service Act 117 
(PHSA) and the Code of Federal Regulations (CFR no. 21, Parts 1270 and 1271 of the FDA 118 
cGTP). Minimal manipulation is defined as negligible alteration to the tissues’ original 119 
biological structure including physical integrity, tensile strength, and elasticity; while 120 
allowing for preservation via drying, cryopreservation, and denuding (removal of 121 
epithelium).[17] FDA regulation does not mandate terminal sterilization for HCT/Ps, 122 
however, aseptic processing must be used during tissue manufacturing to prevent 123 
contamination.[18] 124 
 125 
2.1 Amniotic membrane as an example of a TBTM 126 
AM is a TBTM that has a long history of surgical use, but has varied processing techniques 127 
and associated challenges. AM can be used for membrane repair on wound surfaces, or to fill 128 
spaces left by non-healing ulcers.[19-21] AM is commonly used in ophthalmic applications 129 
to treat a variety of corneal conditions.[5] Alongside acting as a transparent, physical shield, 130 
AM reportedly possesses protective, antimicrobial, analgesic, and anti-inflammatory 131 
properties, that promote wound healing.[5, 6] Due to its healing properties and low 132 
immunogenicity, AM is often applied directly to open wounds. 133 
AM undergoes stringent and tightly regulated processing procedures for clinical application. 134 
AM is typically collected from women undergoing preplanned, full-term elective cesarean-135 
sections.[22] Therefore, donor screening, which involves assessment of information on health 136 
and social history, is the first line in disease transmission prevention. Donors must comply 137 
with set inclusion criteria, for example test-negative for human immune-deficiency virus 138 
(HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Treponema pallidum (syphilis), 139 
among other criteria.[23, 24] 140 
Under normal health, AM is naturally free of bioburden while in the womb. However, normal 141 
flora of the lower genital tract (e.g., gram-positive and gram-negative aerobic and anaerobic 142 
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organisms such as genital mycoplasmas and Streptococcus agalactiae), are capable of 143 
crossing intact membranes to invade the amniotic cavity during labor.[25] However, AM 144 
obtained from healthy full-term cesarean sections should have no bioburden. The UK 145 
advisory committee on Safety of Blood, Tissues and Organs (SaBTO) guidelines state that: 146 
“Estimation of bioburden of skin and amnion is not recommended as the former carries a 147 
substantial bioburden and the latter is surgically recovered under aseptic conditions. However, 148 
a heavy growth of bacteria from pre-process samples may signify gross contamination and 149 
the tissue should not be released unless able to be terminally sterilized by irradiation or other 150 
techniques. The potential damage to the integrity of the tissue by the high numbers of bacteria 151 
should also be considered before it is used for transplantation.”[26] 152 
Cesarean deliveries do have the potential to introduce some contamination, likely originating 153 
from the donor's skin microbial flora, transmitted during AM removal.[27, 28] Other 154 
contamination may arise from the operating room environment. Further processing of AM 155 
usually takes place in GMP environments subjected to high-level decontamination procedures. 156 
AM is generally rendered non-viable during preservation, either by drying or freezing.[29] As 157 
a non-viable tissue, currently used surgically, AM is an ideal candidate for terminal 158 
sterilization. 159 
 160 
3 STERILIZATION OF ABNORMAL BIOLOGICAL CONTAMINANTS 161 
Processing and sterilization protocols are effective for TBTM with low to normal bioburden. 162 
Tissues infected with a high bioburden of endotoxin producing, gram-negative bacteria or 163 
virulent, antibiotic-resistant bacteria, for example pseudomonas, methicillin-resistant S. 164 
aureus (MRSA), or C. difficile, represent a greater hazard and are unsuitable for 165 
transplantation unless a terminal sterilization procedure is used, that is validated for effective 166 
removal or complete inactivation of microbial loads.[30] TBTM can also be contaminated by 167 
non-living biological agents such as endotoxins, prions, and viruses, which are known to 168 
resist most conventional sterilization methods.[31] Most ISO standards exclude viruses and 169 
prions from their sterilization validation documents. For example, ISO 14160:2011[32] for 170 
liquid chemical sterilization controls risks associated with only bacteria and fungi 171 
contamination; however, it is not applicable to TBTM. Also, ISO 11137-1:2006,[33] for 172 
validation of radiation sterilization dose does not cover viral contamination and ISO 173 
11135:2014,[34] for validation and control of EtO sterilization methods excludes prion 174 
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contamination from its scope. Categorically, these standards indirectly recognize the 175 
downsides of industrial sterilization technologies toward particular contaminations. 176 
The risk of harvesting and transplanting infected tissue can be reduced, but not eliminated, by 177 
specific donor exclusion criteria in the form of detailed medical/social history questionnaires 178 
and advanced serological testing. However, terminal sterilization remains the most effective 179 
method for eliminating biological contamination hazards associated with donor source, 180 
procurement, and manufacturing. Selection of the appropriate sterilization protocol for 181 
TBTMs must be considered on a case-by-case basis; considering the possibility of 182 
sterilization resistant contaminants. 183 
3.1 Endotoxins 184 
Endotoxins are the lipopolysaccharides (LPS) that make up the outer membranes of the 185 
pathogenic and non-pathogenic gram-negative bacteria.[35] Endotoxins present in the blood 186 
stream are life-threatening in high doses,[36] due to activation of the immune system causing 187 
“endotoxin shock.” Current sterilization technologies only deactivate endotoxin producing 188 
bacterial species and are incapable of removing endotoxins themselves. Therefore, there is 189 
potential endotoxin existence on sterile products. Endotoxin contamination is of great 190 
concern in pharmaceutical and TBTM manufacturing industries, as they are thermostable, 191 
resistant to pH change, vary widely in size, and have heterogeneous molecular structures.[37, 192 
38] Aggressive endotoxin removal methods such as high temperatures (250 °C for 30 min, or 193 
180 °C for 3 h)[39] are unsuitable for TBTM. The terminal sterilization radiation doses 194 
required to degrade endotoxins are effective only at very high levels,[40] which can be 195 
destructive to TBTM. As product removal of endotoxins is more problematic than 196 
sterilization; avoiding contamination by employing aseptic technique and current good tissue 197 
practice (cGTP) are currently the favored approach. 198 
 199 
3.2 Prions 200 
Prions are another challenging form of non-living contamination. They are a pathogenic form 201 
of misfolded protein responsible for introducing neurodegenerative disorders such as 202 
transmissible spongiform encephalopathies. These potentially fatal prion diseases can be 203 
transmitted to healthy patients through contaminated tissue allografts such dura mater and 204 
ocular tissue transplants.[41] Prions exhibit a resistance to most known physical and chemical 205 
sterilization methods. Even methods combining autoclaving with chemical treatment of 206 
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concentrated sodium hydroxide are incapable of completely abolishing prion contamination 207 
from reusable hospital devices.[42] 208 
 209 
3.3 Biofilm 210 
A biofilm is a complex stratified mass of single or varied genotypes of microbes (bacteria or 211 
fungi), compacted to each other and strongly attached to surfaces. Biofilms have high 212 
protection capacity against disinfectants and antimicrobials compared to normal microbial 213 
form. Thickness and compaction determines microbial biofilm resistance to penetrating 214 
oxidative agents. Biofilms are formed on synthetic transplant materials,[43] but are not 215 
known to be present on TBTM. However, biofilm presence in water pipes, channels, and 216 
surfaces of TBTM manufacturing equipment can be a source of frequent contamination, 217 
representing a considerable safety concern. Once these biofilm making microorganisms reach 218 
the manufacturing equipment and materials, a reliable sterilization technique is required to 219 
eradicate it. Examples of biofilm forming bacteria include: MRSA, Staphylococcus 220 
epidermidis (S. epidermidis), Staphylococcus aureus (S. aureus), and Escherichia coli (E. 221 
coli).[43] 222 
 223 
3.4 Viruses 224 
Non-viable TBTM that have been exposed to chemical treatment, drying or terminally 225 
sterilized are less virally infectious than viable tissue preserved at low temperatures.[44] 226 
Therefore, transmission of viruses through non-viable TBTM is rare. However, viruses with 227 
small, and/or double stranded genomic material have more ability to repair damage to genetic 228 
material than viruses with complex genomes,[45] and can resist high radiation doses of 229 
100 kGy.[46] 230 
 231 
4 ESTABLISHED STERILIZATION TECHNIQUES FOR TBTM 232 
Challenges of TBTM manufacturing include standardization, maintenance of tissue quality, 233 
and sterility, which may ultimately affect clinical outcome. The predominant issue with 234 
contemporary terminal sterilization techniques such as γ, e-beam, and EtO, is maintenance of 235 
tissue structure and biological properties.[47] However, failure to provide sterile TBTM can 236 
result in significant health complications, and cost implications to health care providers. 237 
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4.1 Standardization and regulation of sterilization techniques 238 
High temperature sterilization techniques, such as high-pressure steam methods, are 239 
unsuitable due to their denaturing and destructive effects on tissue extracellular matrix; they 240 
can also coagulate soft tissues[48] and are insufficient for endotoxin inactivation. Other non-241 
thermal, conventional sterilization methods such as EtO, γ, and e-beam are recognized 242 
techniques, which are effective when validated correctly.[42] Radiation dosage for 243 
sterilization is validated using ISO 11137 (2006), EtO, and pressured steam sterilization are 244 
also standardized by ISO 11135 (2014) and ISO 17665-1 (2006)[49] respectively. 245 
The achievement of absolute sterility is difficult to determine without destructively testing all 246 
batch materials.[50] Therefore, sterile production standards of medical supplies, drugs and 247 
TBTMs refer to the sterility assurance level (SAL). SALs are based on the theoretical 248 
probability of overkill and demonstration of non-sterility of a particular item following 249 
sterilization. SAL 10−6 is adopted for medical devices and biological products and is endorsed 250 
by most major tissue banking societies and specialized organizations.[51, 52] Using SAL 251 
10−6 implies that no more than one item in one million may be non-sterile, or that there is a 252 
one in a million chance that an individual microbe will survive sterilization. Nevertheless, the 253 
FDA does not specify a particular method of terminal sterilization or a specific SAL for 254 
TBTMs. SAL selection is the tissue manufacturer's responsibility and appropriate SALs 255 
lower than 10−6 can be used if the product is unable to withstand the sterilization process 256 
(AAMI ST67 standard). SAL 10−3 is used for inanimate medical supplies and have not been 257 
reported to be less assured than SAL 10−6 products in terms of preventing nosocomial 258 
infections2. Although current terminal sterilization techniques have revolutionized many 259 
industries including medicinal products and tissue supply, higher SALs may come at the cost 260 
of damaging TBTM.[53] 261 
 262 
4.2 Limitations of current low temperature sterilizations 263 
Current terminal sterilization techniques along with their advantages and disadvantages with 264 
respect to TBTM are summarized in Table 1. 265 
 266 
 267 
 268 
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Table 1. Physical and chemical terminal sterilization techniques and their advantages and 269 
disadvantages 270 
Technique Advantages Disadvantages 
Physical 
Pressurized steam 
(autoclaving) 
Inexpensive simple, safe, rapid, 
and efficient, leaves no toxic 
residues.[73] 
Incompatible with tissues and 
polymeric biomaterials due to high 
temperature and moisture that disrupts 
biochemical structures and causes 
coagulation of proteins.[42, 168] 
  Easy to monitor.[42] Materials require special permeable 
packages to ensure steam reaches all 
surfaces.[42] 
  Can sterilize liquids.[42]   
  More effective than dry heat 
against prions.[42] 
  
  Used in both industry and clinical 
settings. 
  
Ionizing radiation 
Gamma (γ) radiation 
from 60Co 
Effective against spore forming 
bacteria. 
Predominantly only available in 
industrial and research centers.[42] 
  Radiation doses ≤25 kGy do not 
alter the mechanical performance 
of soft tissues.[169] 
High capital cost for installation and 
maintenance. 
  Suitable for heat and moisture 
sensitive materials. 
Expensive 60Co source 
replenishment.[159] 
  Higher penetration (50–80 cm).[45, 
170] 
Unsuitable for small tissue batch 
producers. 
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Technique Advantages Disadvantages 
  Dose rate approximately 10 kGy/h. Requires high doses to deactivate 
viruses (89 kGy). 
  Immediate release after processing. Higher doses than 35 kGy cause tissue 
damage.[53] 
  No need for permeable packaging. Causes crosslinking and/or peptide 
chain breakage.[53, 168] 
  Leaves no chemical residues or 
radioactive substances.[168, 171, 
172] 
Low dose rate (slow dose delivery).[45] 
  Cost-effective compared to 
EtO.[170] 
Not appropriate for viral or prion 
infected tissue.[33] 
    High doses required to eliminate 
endotoxins.[40] 
Electron (e-beam) radiation Can sterilize heat and moisture 
sensitive materials, and generally 
more compatible than γ.[42] 
High equipment and operational 
cost.[174] 
  Doses up to 34 kGy are less 
harmful on soft tissues.[173] 
Higher doses than 35 kGy damaging to 
tissues. 
  High dose rate (quick sterilization 
dose delivery within minutes).[45] 
High electric consumption.[33] 
  No need for permeable packaging. Not appropriate virally infected human 
donated tissue grafts.[33] 
  Immediate release after processing. Low penetration depth (5–8 cm).[43, 
170] 
  No chemical residues or Not recommended for high density 
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Technique Advantages Disadvantages 
radioactive substances.[168, 171, 
172] 
materials. 
  Cost effective compared to 
EtO.[170] 
Acceptable sterilization doses are not 
effective against prions. 
    Ineffective against endotoxins. 
Chemical 
Ethylene oxide gas (EtO) Reliable and effective 
sterilization.[175] 
Only available and suitable for large-
scale usage. 
  Efficient bactericidal, sporicidal, 
and virucidal activity.[176] 
High costs for small scale use. 
  Rapidly deactivates hepatitis B and 
HIV-1 viruses.[177] 
Lengthy sterilization process.[168, 178] 
  Causes less damage to extracellular 
matrix than γ, e-beam, and 
glutaraldehyde methods.[53] 
Requires special gas-permeable 
packaging.[33] 
  Suitable for bulk sterilization. Recognized as a toxic waste by the 
Environmental Protection Agency 
(EPA).[60, 168, 178-180] 
    Potentially carcinogenic.[60, 181, 182] 
    Process monitoring is more complex 
than radiation, needs to control several 
parameters.[42, 183] 
    Flammable and explosive.[184] 
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Technique Advantages Disadvantages 
    Leaves toxic residues on sterilized 
materials.[168] 
    Causes potential damage to tissues.[60, 
61, 183, 185] 
    Not recommended for sterilization of 
tissue allografts.[180, 185] 
    Danger to facility workers.[186] 
    Ineffective against prions.[34] 
 271 
Ionizing radiation sterilization at moderate doses is used at large-scale for medical supplies 272 
and synthetic prostheses, but there are concerns regarding their destructive effects on TBTMs 273 
at higher doses. γ and e-beam radiation are widely applied for tissue sterilization including 274 
AM.[54-57] Twenty-five kGy from both e-beam and γ sources has been internationally 275 
accepted as a guaranteed dose, however, the International Atomic Energy Agency (IAEA) 276 
standards[58] recommend a dose of below 25 kGy.[30] Conversely, concerns regarding viral 277 
transmission via allografts from deceased donors potentially infected with HIV/HCV/HBV 278 
justify higher doses (e.g., 35 kGy).[54] Debates regarding optimal sterilization dose reflect 279 
concerns regarding unacceptable structural damage or physicochemical changes caused by 280 
high radiation doses[45, 59] and irradiation cost, especially for small tissue manufacturers, is 281 
an additional issue. 282 
Chemical sterilization, such as EtO, has toxicity concerns due to high oxidative stresses of 283 
free radicals and residues, time-consuming processes, expense, and difficult operational 284 
requirements. EtO sterilization unavoidably leaves residuals such as ethylene chlorohydrin 285 
and ethylene glycol on treated products,[60] limiting the functionality of biological 286 
tissues.[61] Other chemical sterilization methods, occasionally used for TBTM; are rarely 287 
regarded as terminal sterilization due to technical, safety, or biocompatibility barriers. Super 288 
critical carbon dioxide (SCCO2),[62] characterized by its efficacy against spores, penetration, 289 
and biomaterial compatibility,[62-65] is reported to cause damage to materials, leaves 290 
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residues, and is ineffective against endotoxins.[53, 66] Vaporized peracetic acid (PAA) gas 291 
plasma, has been proven to have broad germicidal action over short-time periods,[67] and is 292 
compatible with most collagenous materials and tissues.[68-70] However, PAA has time and 293 
cost constraints[71] and additionally, PAA sterilized ophthalmic instruments have been 294 
documented to cause serious ophthalmic and skin damage with contact, leading to withdrawal 295 
from the market place.[64, 72, 73] Similarly, vaporized hydrogen peroxide (H2O2) gas plasma 296 
is used efficiently for TBTM sterilization and is FDA approved.[74, 75] However, it has 297 
problems regarding adverse reactions with the functional properties of the tissue and medical 298 
materials.[76, 77] Glutaraldehyde sterilization protocols are relatively inexpensive, effective 299 
against most bacteria and viruses, but limited by long process cycles and toxicity to recipient 300 
tissues and potentially crosslinking effects.[64] 301 
 302 
5 COLD ATMOSPHERIC PRESSURE GAS PLASMA FOR TERMINAL 303 
STERILIZATION 304 
Plasma3 has been widely investigated for medical applications in recent years. Progressive 305 
findings regarding the role of plasma in the deactivation and elimination of biological 306 
contamination demonstrates the potential for this technology to overcome the drawbacks of 307 
conventional sterilization methods of heat sensitive materials including TBTM. 308 
 309 
5.1 Thermal and non-thermal plasmas 310 
Plasmas at atmospheric pressure can be classified in terms of temperature into two categories, 311 
thermal[79, 80] and non-thermal.[81-83] In thermal plasma, the charged particles, neutral 312 
electrons, and heavy particles all have the same high temperatures (in thermodynamic 313 
equilibrium with the surrounding temperature) and are almost fully ionized; while, in the non-314 
thermal plasma the temperature of gas, atoms, and molecules remains low[84] because of the 315 
slight ionization of the used gas,[79] with only electrons at high temperature. Due to this 316 
variation of the constituent's temperature, non-thermal plasma is also termed non-equilibrium 317 
plasma.[85, 86] 318 
 319 
 320 
  321 
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5.2 Low and atmospheric pressure plasmas 322 
Given that thermal plasma produces high gas temperature, non-thermal “cold” plasma is 323 
much more suitable as an emerging sterilization method,[80, 85] for inactivation of microbial 324 
loads on human tissues and heat sensitive surfaces.[87] Furthermore, cold plasma can be 325 
produced at low pressures, under vacuum, but for practicality and economic reasons, it is 326 
more convenient and cost-effective when generated at atmospheric pressure and therefore 327 
called cold atmospheric-pressure plasma (CAP).[86] 328 
CAP is obtained by exposing gas flow (either air, or noble gases such as oxygen, nitrogen, 329 
argon, or helium) to a high electric field which partially ionizes the gas atoms producing a 330 
sustained plasma. This plasma contains a collection of excited electrons, negative and 331 
positive ions, excited gas species, for example, O, , O3, OH•, reactive oxygen species 332 
(ROS), NO and NO2 reactive nitrogen species (RNS), free radicals, and UV-photons at 333 
different wavelengths.[88] These nontoxic gases become germicidal only after the plasma is 334 
ignited, since they are not biocidal on their own.[89] Concentration of produced plasma 335 
agents (i.e., ROS, RNS, UV, free radicals, charged particles) depends on the operation 336 
parameters of the plasma source; namely loaded gas, gas pressure, flow rate, electric voltage, 337 
etc. 338 
 339 
5.3 CAP systems 340 
CAP can be provided by three different systems (Figure 1): (i) direct plasma, known as the 341 
dielectric barrier discharge (DBD) system. By design, the DBD system safely uses the 342 
material to be sterilized as a grounded electrode, which the current flows through, while the 343 
other electrode is connected to a high voltage; air is utilized as the operating gas, and the 344 
distance between plasma source tip and the object is a few millimeters[79]; (ii) “indirect 345 
plasma,” also known as atmospheric pressure plasma jet, which is deployed by a plasma 346 
needle/pen (narrow focused jet) or plasma torch systems which have broader streams and 347 
cover larger surface areas.[90] These devices generate plasma between two electrodes, 348 
transferred through a gas flow to the object to be treated, the distance between the object and 349 
the device ranges from millimeters to centimeters. The reactive species are generated by 350 
igniting plasma in an operating gas such as air, or by helium or argon plasmas in an 351 
admixture of oxygen or nitrogen[91]; (iii) hybrid systems or coronal discharge, have 352 
characteristics of both direct and indirect plasmas.[79, 92] 353 
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 354 
Figure 1. Schematic diagram showing non-thermal, cold atmospheric pressure plasma system 355 
types 356 
 357 
5.4 Mechanisms of microbial inactivation by CAP 358 
CAP technologies have been used effectively to eliminate microorganisms on living tissues in 359 
several clinical applications,[8, 79, 93-100] including inactivation and eradication of fungi, 360 
and vegetative and spore-forming bacteria.[85, 88, 101] The microbial inactivation effect of 361 
CAP can be attained by direct exposure to both the ignited plasma discharge products such as 362 
ROS, RNS, UV radiation, or indirectly through the long-lived species that are capable to 363 
reach the treated substrate without the electric field effect.[90] Generally, decontamination 364 
through plasma treatment is accomplished via oxidative stress arisen from synergetic actions 365 
of plasma discharge products.[87, 102] 366 
The specific plasma agent responsible for the mechanism of CAP killing is not clearly 367 
corroborated in literature[7, 88]; although CAP is proven to be damaging to bacterial cell 368 
walls, primarily due to ROS and RNS.[103] These charged particles have sufficient ability to 369 
induce high oxidative stress which cause damage in microbial cells via fast direct 370 
interactions.[80] It has been postulated that the accumulation of plasma charged particles 371 
over the bacterial cell membrane causes membrane rupture through electrostatic 372 
disruption[104]; or that the reactive species permeabilize and penetrate the cell walls before 373 
reacting with DNA via complex mechanisms.[105] Membrane damage through lipid 374 
peroxidation is another major cause of bacterial death by CAP. The effect by heat and UV is 375 
argued to be indirect or negligible.[106, 107] However, CAP's microbicidal action produced 376 
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by various plasma sources are reported to target viable cellular components such cell 377 
membrane, protein, and DNA. The effect of CAP is believed overwhelming the DNA repair 378 
mechanisms of the bacterial cells.[7] 379 
 380 
5.5 Effects of CAP on vegetative and spore-forming bacteria 381 
Plasma agents destroy different microbial entities irrespective of their molecular defense 382 
mechanisms. Examples reported of CAP capability for decontaminating multidrug resistant 383 
bacteria including the highly resistant MRSA[108-110] and Pseudomonas aeruginosa.[109] 384 
Notably, CAP is also effective on the sterilization resistant Deinococcus radiodurans (D. 385 
radiodurans) bacteria.[111] Less resistant vegetative bacteria have also been tested against 386 
the antimicrobial activity of CAP, and were eliminated with different degrees of survival, 387 
including gram-negative: E. coli,[110, 112, 113] Salmonella typhimurium,[114] and gram-388 
positive S. epidermidis,[89, 112, 115] S. aureus,[89, 113] Micrococcus 389 
luteus,[94] Streptococcus pyogenes,[89] Enterococcus faecalis (E. faecalis),[116] 390 
and Enterococcus faecium.[89] Gram-negative bacteria are more susceptible to gas plasma 391 
treatments than gram-positive[103, 117] and differences in susceptibility are thought to be 392 
due to variation in the thickness of the peptidoglycan murein layer in the bacterial cell 393 
wall.[85, 103] 394 
Skin floral bacteria S. epidermidis is of particular importance in sterilization of TBTM given 395 
its frequent association with contamination from procurement and processing sites. It is 396 
normally found in the hair follicle where it is protected from antiseptics. CAP penetration has 397 
the capacity to reach deep into hair follicles[118] and disinfect bacteria by 94%.[119] Gram-398 
positive skin flora Propionibacterium acnes (P. acnes), reported to cause post-transplantation 399 
and implantation infection, are also effectively sterilized by CAP even in protected 400 
aggregated forms.[120] 401 
Spore-forming bacteria are typically resistant to many established sterilization protocols, and 402 
are often used as a model organism for sterilization verification. Studies have demonstrated 403 
CAP efficacy against bacterial spores, including: Bacillus subtilis (B. subtillis), C. 404 
difficile, Bacillus atrophaeus (B. atrophaeus), Bacillus safensis (B. safensis), Bacillus 405 
megaterium (B. megaterium), B. megaterium 2c1, and Bacillus thuringiensis (B. thuringiensis) 406 
E24.[121, 122] Studies have shown CAP has effective sporicidal action even in humid 407 
conditions,[123, 124] when spores are stacked together or covered by debris. 408 
  409 
18 
 
5.6 Effect of CAP on abnormal contamination 410 
TBTM manufactured in a sterile environment using cGTP protocols are unlikely to have 411 
resistant contamination such as endotoxins, prions, viruses, and biofilms unless a pre-412 
processing infection has occurred. Efficient sterilization should be able to inactivate all forms 413 
of disease causing contamination. The advantage of CAP sterilization compared to traditional 414 
methods is its powerful efficacy to eliminate resistant contamination and removal through its 415 
etching action, which is highly dependent upon applied plasma source. For instance, plasma 416 
jets have more etching capabilities than DBD systems. The plasma density, gas mixture, and 417 
radical content are important parameters in etching of protein residues from treated surface 418 
by chemical degradation and volatilization mechanisms.[125] CAP has been demonstrated to 419 
be effective for inactivation of LPS endotoxin removal from treated surfaces within 420 
minutes.[126, 127] Similarly, it has been shown that CAP is efficient in removing amyloid 421 
fibril aggregates (protein structure mimics prion) from a surfaces, and that aggregates outside 422 
the plasma diameter were degraded, while those within the plasma focus were consistently 423 
removed.[128] The use of a CAP system with a negative corona discharge has been shown to 424 
have a significant effect on prions and may reduce the infectivity of prion particles by several 425 
orders of magnitude.[129] This was believed to be mediated by the generated reactive 426 
particles. Additionally in this study, the source of CAP had different effects on the viability 427 
of brain cells; a positive streamer discharge killed the cells, whereas point-to-point, cometary, 428 
and negative corona discharges did not result in a loss of cell viability. This indicates that the 429 
discharge configuration is an important parameter to consider when sterilizing viable tissues 430 
with CAP. 431 
TBTM contaminants such as the anaerobic gram-positive P. acnes and Staphylococcus have 432 
been proven to form in vivo and in vitro biofilms, and develop resistance to gentamicin-433 
loaded implants for orthopedic surgery,[43] causing biomaterial/prosthesis transplant 434 
infection and failure.[130] Biofilms of P. acnes bacteria have been found to be considerably 435 
inactivated by two types of plasma jet over short-time periods.[120] Biofilms of MRSA, S. 436 
epidermidis, S. aureus, and E. coli are also removed by CAP treatment.[12] Similarly, CAP 437 
have efficiently removed biofilms of antifungal resistant Candida albicans (C. albicans).[131] 438 
This effect can potentially be enhanced by adding oxygen to the plasma discharge.[132] 439 
Studies have shown that viruses can be eliminated by CAP, due to the destruction of the 440 
protein coat, rather than a direct effect on viral DNA.[133] 441 
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Several factors may affect the dose or the exposure time required to achieve sterilization. 442 
These factors are related to the plasma device operational conditions or the microorganism 443 
conditions before and after exposure, e.g., bacterial species, bacterial culture age (growth 444 
phase), bacterial medium during, and post-treatment.[134] The eradicating effect of CAP on 445 
various microorganisms is well-established in literature,[90, 129] however, studies on 446 
sterilization and removal of biological non-living disease causing agents would have a 447 
promising medical applications.[13, 129] However, CAP system variation, the flexibility of 448 
utilizing variable operational conditions along with the different applications have resulted in 449 
complication when comparing the literature findings. Table 2 shows examples of the 450 
sensitivity of microorganisms of medical importance and other biological contaminants 451 
resistant to sterilization, treated with different CAP devices under various experimental 452 
conditions, with differences in exposure times and contamination reductions. CAP device 453 
specifications and the applied dose were omitted due to the aforementioned plasma delivery 454 
complexities. Often, the time required to inactivate or sterilize the microbial/biological 455 
contaminations is much shorter than those applied in other established sterilization methods 456 
regardless of the CAP system used. To achieve SAL 10−6 sterilization, exposure duration 457 
(plasma dose) may be extended. Therefore, it is important to have information on the level of 458 
initial material contamination if CAP is chosen as a sterilization protocol. It can be difficult to 459 
contrast and compare CAP efficacy on biological contamination due to the variability in CAP 460 
parameters and systems; however, this does not indicate that CAP is ineffective. 461 
Table 2. Examples of susceptibility of vegetative bacteria, fungi, bacterial spores, endotoxins, 462 
prions, and biofilm to CAP treatment 463 
  464 
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 465 
Microorganism Importance Exposure substrate 
Log 
reducti
on 
or % 
sterili-
zation 
Expos
ure 
time 
(s) 
Ref 
 aKCTC, Korean Collection for Type Cultures, Korea. 
 bATCC, American Type Culture Collection, USA. 
 cDSM, Leibnitz Institute DSMZ-German Collection of Microorganism and Cell Cultures, 
Germany. 
 dNA, not available. 
Vegetative bacteria (gram-negative) 
E. coli Clinical pathogen Agar 
medium 
plates 
5 log 600 [12
2] 
E. coli Clinical pathogen Glass 
slides 
100% 1 [18
7] 
E. 
coli KCTCa 1039 
Clinical pathogen Thin glass 
covers 
10 log 7 [12
1] 
      100% 60   
E. coli O157:H7 
(C9490) 
Foodborne 
pathogens 
Dry 
almonds 
1.34 
log 
20 [18
8] 
E. coli 
O157:H7 (ATCCb
35150) 
          
E. coli O157:H7 
(ATCC 43894) 
          
Salmonella 
anatumF4317 
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Microorganism Importance Exposure substrate 
Log 
reducti
on 
or % 
sterili-
zation 
Expos
ure 
time 
(s) 
Ref 
Salmonella 
stanleyH0558 
          
Salmonella 
enteritidisPT30 
          
Vegetative bacteria (gram-positive) 
P. acnes KCTC 
3314 
Skin flora Coated 
glass 
slides 
7 log 600 [12
0] 
D. radiodurans Radiation, drying, 
and oxidizing 
agent resistant 
Aluminu
m discs 
3 log 1800 [12
2] 
Lactobacillus 
acidophilus 
Oral caries 
producing bacteria 
Hydroxya
-patite 
1.5–2 
log 
6 [18
9] 
Streptococcus 
mutans 
          
Listeria 
innocua (ATCC 
33090) 
Non-pathogenic 
surrogate for the 
foodborne 
pathogen monocyt
ogenes 
Chicken 
meat and 
skin 
3.3 log 480 [15
0] 
Fungi 
C. 
albicans (thickness 
of 10–20 mm) 
Pathogenic fungus Polystyren
e wafers 
95% 300 [13
2] 
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Microorganism Importance Exposure substrate 
Log 
reducti
on 
or % 
sterili-
zation 
Expos
ure 
time 
(s) 
Ref 
C. albicans Antifungal 
resistant 
(fluconazole-
resistance) 
Air >90% 600 [19
0] 
Candida krusei   Water >90% 60   
Candida glabrata           
Aspergillus 
flavus (ATCC 327) 
Mycotoxin 
producing food 
contaminants 
Hazelnuts 4.50 
log 
300 [19
1] 
Aspergillus 
parasiticus(ATCC 
1041) 
    4.19 
log 
    
Aspergillus 
parasiticus798 
TUBITAK-MAM 
Bio-indicator 
fungus 
Vegetable 
and 
legumes 
seed 
surfaces 
3 log 900 [19
2] 
Penicillum MS198
2 
          
Spore-forming bacteria 
B. subtilis Sterilization 
resistant 
Thin glass 
covers 
10 log 24 [12
1] 
      100% 120   
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Microorganism Importance Exposure substrate 
Log 
reducti
on 
or % 
sterili-
zation 
Expos
ure 
time 
(s) 
Ref 
B. 
safensis, DSMc19
292T 
Sterilization 
resistant 
Aluminu
m discs 
>6 log 3600 [12
2] 
B. megaterium, 
ATCC 14581T 
    100% 5400   
B. 
megaterium DSM 
30587 (2c1) 
          
B. 
atrophaeus DSM6
75 
Sterilization 
resistant 
Aluminu
m discs 
>3 log 5400 [12
2] 
B. 
thuringiensis DSM 
30879 (E24) 
          
B. subtilis Sterilization 
resistant 
Glass 
slide and 
aluminum 
substrates 
4 log 
(He 
plasma
) 
<600 [19
3] 
      8 log 
(air 
plasma
) 
    
B. atrophaeus Biological 
indicator for 
thermal 
sterilization (heat 
resistant) 
Commerci
al spore 
strip 
≥6 
log 10 
60 [12
4] 
24 
 
Microorganism Importance Exposure substrate 
Log 
reducti
on 
or % 
sterili-
zation 
Expos
ure 
time 
(s) 
Ref 
Endotoxins 
LPS from E. 
Coli ATCC 8739 
Pyrogen Glass 
slides 
100% 10 [18
7] 
Viruses 
Adenovirus, non-
enveloped double 
stranded DNA 
virus 
Human infectious 
disease causing 
PBS 
solution 
6 log 240 [13
] 
Bacteriophage 
lambda (λ phage) 
Virus that infects 
bacteria 
Buffer 6 log 20 [13
3] 
Bacteriophage 
lambda (λ phage) 
C-17 (ATCC 
23724-B1) 
Virus that infects 
bacteria 
NAd 4–6 
log 
600 [19
4] 
Lytic 
bacteriophage 
(rambo; 
microphage) 
          
MS2 
bacteriophage 
ATTC 15597-B1 
Surrogate of 
human enteric 
viruses such as 
norovirus that 
causes infectious 
gastroenteritis 
Phage 
suspensio
n 
4.98–
7.06 
log 
450 [19
5] 
Influenza virus 
type A (H5N2) 
Airborne 
respiratory 
Viral 
aerosol 
4 log 
(99.20
180 [19
6] 
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Microorganism Importance Exposure substrate 
Log 
reducti
on 
or % 
sterili-
zation 
Expos
ure 
time 
(s) 
Ref 
pathogen suspensio
n 
%) 
Human 
parainfluenza virus 
type 3 strain C-243 
ATCC VR-93 
    6.5 log 
(99.22
%) 
    
Respiratory 
syncytial virus-A 
ATCC VR-26 
    3.8 log 
(99.00
%) 
    
Prions 
Scrapie (Rocky 
Mountain 
Laboratory strain, 
RML5) 
Surrogate of 
human prion 
1% mouse 
brain in 
PBS 
solution 
100% 600–
1200 
[12
9] 
Biofilm 
P. 
aeruginosa SG81 
Clinical pathogen Polycarbo
nate discs. 
4.83 
log 
300 [11
7] 
      7.11 
log 
600   
S. 
epidermidis RP62
A 
Skin flora Polycarbo
nate discs 
2.77 
log 
300 [11
7] 
      3.38 
log 
600   
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Microorganism Importance Exposure substrate 
Log 
reducti
on 
or % 
sterili-
zation 
Expos
ure 
time 
(s) 
Ref 
Salmonella 
enterica serovar 
typhimurium 
Clinical pathogens Lettuce 5 log 300 [19
7] 
Listeria 
monocytogenes 
          
E. coli           
E. faecalis           
C. albicans Clinical pathogen Inanimate 
surface 
6 log 240 [13
1] 
 466 
5.7 Use of CAP for TBTM sterilization 467 
CAP has been evaluated as a safe and efficient procedure for decontamination of skin wounds, 468 
ulcers, and infected tissues in patients, and there are commercially available products such as 469 
the kINPen[135] and the DBD plasma generator (PlasmaDerm® VU-2010).[136] Reports 470 
often emphasize the biocompatibility of plasma treatment on viable cells and tissues, 471 
including ocular surface tissues.[100, 137-139] These effects are deleterious to microbial 472 
contamination, but have thus far not been proved to induce necrotic, apoptotic, or 473 
morphological changes in surrounding tissues. Furthermore, no significant effects on living 474 
cell viability were reported.[110] In other studies, a slight reduction in viability through 475 
necrosis of in vitro culture of mucosal cells was observed, however, no mutagenic effects 476 
were observed.[135, 140] The reason CAP mechanisms are generally harmless to human cells 477 
and tissue is attributed to CAP's superficial penetration,[126, 141] and potentially that 478 
multicellular eukaryotic tissues have more complicated mechanisms to enable survival of 479 
oxidative stresses introduced by plasma agents, than prokaryotic cells.[142] Limited 480 
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penetration could be an obstacle to CAP sterilization of TBTM with thick, heterogeneous size, 481 
and architecture such as bone graft materials.[141] However, dried, thin, soft tissues such as 482 
skin, facia, dura mater, AM, tendons, and laminate of cartilage and bone are all candidates for 483 
CAP sterilization.[143] The defined advantages and disadvantages of CAP sterilization of 484 
TBTM are listed in Table 3. 485 
 486 
Table 3. Advantages and disadvantages of CAP sterilization of TBTM 487 
Advantages Disadvantages 
Biocompatible with viable and non-viable 
tissues. 
Methods not yet validated. 
No toxic chemical residue left on treated 
object.[135] 
Low penetration power so may be not 
suitable for thick TBTM materials.[141] 
Shorter exposure time than established 
sterilization methods (seconds to minutes). 
Difficult to apply to packaged materials. 
No toxic effects to operators and the 
environment.[198] 
Not validated as terminal sterilization 
that offers SAL of 10−6. 
Can remove bacterial cells and viruses from 
sterilized surfaces. 
Many parameters (e.g., loaded gas, gas 
pressure, flow rate, voltage, exposure 
time, and sample distance) need to be 
controlled to get the desired capacity of 
charged species. 
Effective on endotoxins, prions and bacterial, 
and fungal biofilms.[131] 
  
Delivers uniform treatment to uneven surfaces 
of biological materials.[199] 
  
CAP gas capable of reaching confined and 
narrow spaces.[81] 
  
Microorganism resistance to CAP is unlikely to   
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Advantages Disadvantages 
occur.[105] 
Inexpensive.[200]   
Can be used portably or in smaller scale (such 
as in laminar flow hoods and isolators).[200] 
  
 488 
5.8 CAP as a potential technique for thin tissue sterilization 489 
At the time of this review, there were no studies available evaluating CAP for sterilization of 490 
non-viable TBTM. However, if we consider non-viable AM as an example, a number of 491 
factors should be considered when optimizing CAP specifically, tissue thickness, treatment 492 
area, surface morphology, probable type and count of contamination, and whether 493 
sterilization will occur before or after packaging. 494 
A reliable sterilization method must have sufficient penetration capability. Studies have 495 
demonstrated that CAP delivers ROS in the range of 150–1500 µm[144] when employed on a 496 
tissue-equivalent material and at over 5000 µm for agarose gels.[100] For intact viable skin, 497 
reactive species can penetrate up to 10 µm depth.[135] The penetration of H2O2 produced by 498 
CAP into euthanized rat skin and chicken breasts was shown to go up to 4000 µm.[145] 499 
Furthermore, experiments on polyester fabric materials assert that the distance from plasma 500 
nozzle to substrate, exposure time, and thickness of substrate, have an effect on plasma 501 
penetration, yet suggests longer exposure time renders a sufficient amount of reactive species 502 
accumulating on one side to diffuse to the other side of the porous material.[146, 147] 503 
Moreover, it has been demonstrated that nitric oxide (NO) generated by topical application of 504 
DBD over a human skin and reconstructed epidermiswere safe on living tissue and able to 505 
penetrate and cause changes in microcirculation up to 6000–8000 µm on treated skin 506 
areas.[148] Dried AM with a thickness of approximately 20 μm[149] will therefore lie within 507 
the penetration range of CAP and should not require lengthy exposure times. 508 
Surface topography of treated tissue present challenges in sterilization, as changes can occur 509 
during chemical or mechanical processing, creating rough surfaces and microgrooves where 510 
microorganisms can reside and proliferate. Tissue surface irregularity enables contaminant 511 
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bacteria to migrate from the surface into the tissue, protecting it from the biocidal effect of 512 
sterilization.[150] There are natural intercellular microholes on AM epithelial surface 513 
(Figure 2A and B), which have been proven to allow gas transmission through dried and 514 
cryopreserved AM upon transplantation.[151, 152] These microholes are impermeable to 515 
bacteria such as E. coli, Pseudomonas, Klebsiella, and Staphylococcus.[153] CAP can easily 516 
reach narrow, confined spaces, and microgrooves on surfaces.[81] and mobility of plasma gas 517 
can allow for treatment of microspaces.[122, 154] Recent studies reported CAP efficacy in 518 
reducing microbial contamination adhered to rough surfaces of chicken skin,[150] titanium 519 
implant surfaces,[155] and root canals, especially in dry state conditions.[156] This supports 520 
the appropriate use of CAP for sterilization of dry AM with a comparably soft homogenous 521 
surface (Figure 2A and C). 522 
 523 
Figure 2. Scanning electron microscopy image of dried AM (A and B − epithelial side; C and 524 
D − stromal side). (A) Intact polygonal epithelial surface cells with occasional intercellular 525 
spaces (scale bar: 10 μm). (B) Box in (A) magnified to show distinct natural intracellular 526 
microholes (white circles) around the cell (scale bar: 1 μm). (C) Smooth regular stromal 527 
surface of AM (scale bar: 10 μm). (D) Collagen fibrils on the stromal side with tiny 528 
microgrooves (white arrows), scale bar: 1 μm) 529 
 530 
Additionally, CAP treatment of large tissues requires a plasma source capable of delivering 531 
plasma components over wider surface areas. Single CAP jets are limited to a few 532 
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millimeters, for example, 25 mm2,[157] thus are unsuitable, but micro-discharge plasma 533 
devices have been used effectively for biofilm treatment on a 177 cm2 surface area.[131] 534 
Plasma torches are able to treat areas of approximately 25 cm2 and DBD and jet torches 535 
appear to be favorable for large size membranous grafts[81] and have potential to be 536 
developed to operate as a systemic scanning system for tissue materials with large surface 537 
area. The area of AM grafts are generally 4–100 cm2, thus CAP systems could be developed 538 
to accommodate this. 539 
There are parameters related to the plasma system operational conditions that will affect use, 540 
such as: the voltage, loaded gas, gas pressure, flow rate, exposure time, and sample distance 541 
from plasma nozzle.[158, 159] The interplay of these parameters could yield sufficient 542 
plasma density and composition, or conversely might change the treatment outcome; causing 543 
inconsistency in sterilization cycles.[160] For instance, operational parameters such as ion 544 
and UV flux, electric field, and gas flow might not have direct influence on the antibacterial 545 
efficiency, while other factors related to the method and conditions of application such as 546 
distance from the plasma nozzle and exposure time have a distinct influence on treatment 547 
efficiency.[161] 548 
An effective treatment that causes no damage to tissues requires a highly standardized, 549 
balanced, and homogenous current discharge,[162] which can be attained by adjusting the 550 
circuit, gas flow, and power supply parameters.[87] As varied modalities of CAP systems 551 
have been used as decontamination tools on different biological substrates, such as human 552 
skin and food products, it is possible to develop a CAP device that copes with thin non-viable 553 
membranous tissue sealed in sterile packaging. 554 
To maintain sterility of a manufactured TBTM, CAP should be applied after packaging or in-555 
package and sealed in a sterile environment. Use of CAP for in-package sterilization has been 556 
tested effective against spores, used to decontaminate foods, and is compatible with some 557 
packaging materials.[124, 163] DBD plasma configurations developed with efficient 558 
sporicidal actions were found to safely fit several shapes of Tyvek packaging materials used 559 
for sterile wrapping of medical instruments.[164] Different packaging materials including 560 
polyethylene, polypropylene, and nylon loaded with microbial pathogens have shown no 561 
change in the physical properties after treatment with low pressure plasma.[165] Recent 562 
studies have shown that generating plasma inside a closed environment can prevent post-563 
packaging contamination of sterilized products.[166] 564 
Another attractive advantage of CAP over conventional sterilization is cost-efficiency. Cold 565 
plasma generators can be scaled-down as portable devices in a regular laboratory instrument 566 
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size, for use on the bench, which suits application in small-scale tissue production.[8] Close 567 
proximity to tissue preparation site can potentially minimize cost of logistics and are not as 568 
complex as performing terminal sterilization away from the production site. 569 
Direct or indirect CAP systems may be appropriate for AM sterilization, as they can be 570 
operated at atmospheric pressure and at nearly ambient temperature,[167] can deliver large 571 
quantities of active species with sufficient penetration power of plasma agents,[80] and can 572 
treat reasonably large areas inside the final product packaging. Small mobile handled CAP 573 
devices could be an economical choice for AM sterilization inside the sterile area or 574 
alternately, an on-bench contained chamber design for in-package sterilization may be more 575 
applicable. 576 
 577 
6 CONCLUSION 578 
Current terminal sterilization methods such as EtO, ionizing radiation, and chemical 579 
sterilization methods have several disadvantages including toxicity, high running-costs, and 580 
inefficacy against abnormal contamination. CAP is a terminal sterilization technique that is 581 
applicable to living tissues without known harm or side effects, that has been proven to 582 
destroy both normal and abnormal contamination. CAP is inexpensive but limited by tissue 583 
thickness, post-packaging penetration, and reproducibility. Choice of CAP for TBTM 584 
sterilization should be done on individual basis, dependent on tissue characteristics, 585 
manufacturing protocol, and intended use. However, if CAP can be adapted for TBTM, it 586 
holds a vast amount of promise. 587 
 588 
ACKNOWLEDGMENTS 589 
The authors alone are responsible for the content and writing of the manuscript. Funding 590 
from The Authority for Research, Science, and Technology of the Ministry of Higher 591 
Education and Scientific Research-Libya (Scholarship 404/2013) is gratefully acknowledged. 592 
  593 
32 
 
 594 
REFERENCES 595 
1 596 
B. J. Lambert, T. A. Mendelson, M. D. Craven, AAPS Pharm. Sci. Tech. 2011, 12, 1116. 597 
CrossRef | Web of Science® Times Cited: 13 598 
2 599 
D. Hussong, AAPS Pharm. Sci. Tech. 2010, 11, 1482. 600 
CrossRef | Web of Science® 601 
3 602 
S. Stevenson, Orthop. Clin. North. Am. 1999, 30, 543. 603 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 117 604 
4 605 
T. Boyce, J. Edwards, N. Scarborough, Orthop. Clin. North. Am. 1999, 30, 571. 606 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 170 607 
5 608 
H. S. Dua, J. A. Gomes, A. J. King, V. S. Maharajan, Surv. Ophthalmol. 2004, 49, 51. 609 
CrossRef | PubMed | Web of Science® Times Cited: 305 610 
6 611 
F. Gindraux, R. Laurent, L. Nicod, B. de Billy, C. Meyer, N. Zwetyenga, L. Wajszczak, P. 612 
Garbuio, L. Obert, Recent Pat. Regen. Med. 2013, 3, 193. 613 
7 614 
J.-W. Lackmann, J. E. Bandow, Appl. Microbiol. Biotechnol. 2014, 98, 6205. 615 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 14 616 
8 617 
P. Brun, M. Vono, P. Venier, E. Tarricone, V. Deligianni, E. Martines, M. Zuin, S. Spagnolo, 618 
R. Cavazzana, R. Cardin, I. Castagliuolo, A. L. Valerio, A. Leonardi, PLoS ONE 2012, 7, 14. 619 
CrossRef | Web of Science® Times Cited: 32 | ADS 620 
9 621 
C. Hoffmann, C. Berganza, J. Zhang, Med. Gas Res. 2013, 3, 21. 622 
CrossRef | PubMed 623 
10 624 
C. Ulrich, F. Kluschke, A. Patzelt, S. Vandersee, V. A. Czaika, H. Richter, A. Bob, J. Hutten, 625 
C. Painsi, R. Huge, A. Kramer, O. Assadian, J. Lademann, B. Lange-Asschenfeldt, J. Wound 626 
Care 2015, 24, 198. 627 
33 
 
CrossRef 628 
11 629 
R. Laurita, F. Alviano, C. Marchionni, P. M. Abruzzo, A. Bolotta, L. Bonsi, V. Colombo, M. 630 
Gherardi, A. Liguori, F. Ricci, M. Rossi, A. Stancampiano, P. L. Tazzari, M. Marini, J. Phys. 631 
D 2016, 49, 364003. 632 
CrossRef | Web of Science® | ADS 633 
12 634 
M. Hee Lee, B. Joo Park, S. Chang Jin, D. Kim, I. Han, J. Kim, S. O. Hyun, K.-H. Chung, J.-635 
C. Park, New J. Phys. 2009, 11, 115022. 636 
CrossRef | Web of Science® Times Cited: 28 | ADS 637 
13 638 
J. L. Zimmermann, K. Dumler, T. Shimizu, G. Morfill, A. Wolf, V. Boxhammer, J. Schlegel, 639 
B. Gansbacher, M. Anton, J. Phys. D 2011, 44, 505201. 640 
CrossRef | CAS | Web of Science® Times Cited: 33 | ADS 641 
14 642 
J. Komender, Ann. Transplant. 2004, 9, 88. 643 
PubMed 644 
15 645 
Council of Europe, Guide to Safety and Quality Assurance for Organs, Tissues and Cells, 2nd 646 
ed., Council of Europe Publishing, Strasbourg, Belgium 2004. 647 
16 648 
H. Gillan, K. Bennett, P. Yates, Review of Long-Term Storage of Tissue Products, N.B.a. 649 
Trnasplant, Editor. 2010, NHS Blood and Transplant: UK. 650 
17 651 
F. D. A. U.S. Department of Health and Human Services, Minimal Manipulation of Human 652 
Cells, Tissues, and Cellular and Tissue-Based Products − Draft Guidance for Industry and 653 
Food and Drug Administartion Staff. FDA, New Hampshire Avenue, Silver Spring, USA 654 
2014. 655 
18 656 
S. Kuroda, A. S. Virdi, Y. Dai, S. Shott, D. R. Sumner, Calcif. Tissue Int. 2005, 77, 212. 657 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 30 658 
19 659 
I. Mermet, N. Pottier, J. M. Sainthillier, C. Malugani, S. Cairey-Remonnay, S. Maddens, D. 660 
Riethmuller, P. Tiberghien, P. Humbert, F. Aubin, Wound Repair Regen. 2007, 15, 459. 661 
34 
 
Wiley Online Library | PubMed | Web of Science® Times Cited: 67 662 
20 663 
F. E. Kruse, K. Rohrschneider, H. E. Völcker, Ophthalmology 1999, 106, 1504. 664 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 180 665 
21 666 
M. T. Rodríguez-Ares, R. Touriño, M. J. López-Valladares, F. Gude, Cornea 2004, 23, 577. 667 
CrossRef | PubMed | Web of Science® Times Cited: 53 668 
22 669 
P. J. Adds, C. Hunt, S. Hartley, Br. J. Ophthalmol. 2001, 85, 228. 670 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 19 671 
23 672 
Current Good Tissue Practice, American Association of Tissue Banks, McLean, Virginia. 673 
2006. 674 
24 675 
International Standards for Tissue Banks, World Scientific, Singapore. 2003. 676 
25 677 
C. A. Combs, T. J. Garite, J. A. Lapidus, J. P. Lapointe, M. Gravett, J. Rael, E. Amon, J. K. 678 
Baxter, K. Brady, W. Clewell, Am. J. Obstet. Gynecol. 2015, 212, 482. 679 
PubMed 680 
26 681 
SaBTO, Retrieval of Material for Donation Testing. Infectious Diseases and Blood Policy, 682 
UK 2011. 683 
27 684 
S. Hill, AORN J. 2008, 88, 731. 685 
CrossRef | PubMed 686 
28 687 
H. R. Aghayan, P. Goodarzi, A. Baradaran-Rafii, B. Larijani, L. Moradabadi, F. Rahim, B. 688 
Arjmand, Cell Tissue Bank 2013, 14, 401. 689 
CrossRef | PubMed | Web of Science® Times Cited: 2 690 
29 691 
A. Hopkinson, R. McIntosh, P. Tighe, D. James, H. S. Dua, Invest. Ophthalmol. Vis. Sci. 692 
2006, 47, 4316. 693 
CrossRef | PubMed | Web of Science® Times Cited: 57 694 
30 695 
35 
 
J. Morales Pedraza, A. Lobo Gajiwala, M. E. Martinez Pardo, Cell Tissue Bank 2012, 13, 15. 696 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 1 697 
31 698 
N. Yusof, A. Hassan, A. R. Shamsudin, A. C. Yong, M. N. F. A. Rahman, H. Mohamad, 699 
Sterilisation of Tissues Using Ionising Radiations (Eds.: J. F. Kennedy, G. O. Phillips, P. A. 700 
Williams), Woodhead Publishing Limited, Abington, Cambridge, England 2005, p. 319. 701 
CrossRef 702 
32 703 
ISO-14160, Sterilization of health care products − Liquid chemical sterilizing agents for 704 
single-use medical devices utilizing animal tissues and their derivatives − Requirements for 705 
characterization, development, validation and routine control of a sterilization process for 706 
medical devices, in The International Organization for Standardization. 2011 Geneva, 707 
Switzerland. 708 
33 709 
ISO-11137-1, Sterilization of health care products, Radiation, Part 1, Requirements for 710 
development, validation and routine control of a sterilization process for medical devices, in 711 
International Organization for Standardization. 2006: Geneva, Swetzerland. 712 
34 713 
ISO-11135, Sterilization of health care products − Ethylene Oxide − Requirements for 714 
development, validation, and routine control of a sterilization process for medical devices, in 715 
International Organization for Standardization. 2014: Geneva, Switzerland. 716 
35 717 
G. Ramachandran, Virulence 2014, 5, 213. 718 
CrossRef | PubMed | Web of Science® Times Cited: 27 719 
36 720 
N. Mamalis, H. F. Edelhauser, D. G. Dawson, J. Chew, R. M. LeBoyer, L. Werner, J. 721 
Cataract Refract. Surg. 2006, 32, 324. 722 
CrossRef | PubMed | Web of Science® Times Cited: 116 723 
37 724 
E. T. Palva, P. H. Makela, Eur. J. Biochem. 1980, 107, 137. 725 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 331 726 
38 727 
R. C. Goldman, L. Leive, Eur. J. Biochem. 1980, 107, 145. 728 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 353 729 
36 
 
39 730 
T. Miyamoto, S. Okano, N. Kasai, Appl. Environ. Microbiol. 2009, 75, 5058. 731 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 9 732 
40 733 
H. Mrazova, J. Koller, G. Fujerikova, P. Babal, Cell Tissue Bank 2014, 15, 429. 734 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 2 735 
41 736 
P. S-Juan, H. J. T. Ward, R. De Silva, R. S. G. Knight, R. G. Will, Br. J. Ophthalmol. 2004, 737 
88, 446. 738 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 6 739 
42 740 
S. Lerouge, Sterilization of Biomaterials and Medical Devices (Eds.: S. Lerouge, A. 741 
Simmone), Woodhead Publishing Limited, Cambridge, UK 2012, p. 10. 742 
CrossRef 743 
43 744 
M. M. Tuney, M. M. Tunney, N. Dunne, G. Einarsson, A. McDowell, A. Kerr, S. Patrick, J. 745 
Ortho. Res. 2007, 25, 2. 746 
Wiley Online Library | CAS | Web of Science® Times Cited: 37 747 
44 748 
P. Solves, V. Mirabet, M. Alvarez, World J. Gastroenterol. 2014, 20, 7434. 749 
CrossRef | PubMed | Web of Science® Times Cited: 1 750 
45 751 
M. Silindir, A. Yekta Ozer, FABAD J. Pharm. Sci. 2009, 34, 43. 752 
46 753 
N. Yusof, Radiation in Tissue Banking − Basic Science and Clinical Applications of 754 
Irradiated Tissue Allografts (Eds.: A. Nather, N. Yusof, N. Hilmy), © World Scientific 755 
Publishing Co. Pte. Ltd., Singapore 2007, p. 129. 756 
47 757 
D. R. McAllister, M. J. Joyce, B. J. Mann, C. T. Vangsness, Jr., Am. J. Sports Med. 2007, 35, 758 
2148. 759 
CrossRef | PubMed | Web of Science® Times Cited: 69 760 
48 761 
F. von Versen-Hoynck, C. Syring, S. Bachmann, D. E. Moller, Cell Tissue Bank 2004, 5, 45. 762 
CrossRef | PubMed 763 
37 
 
49 764 
ISO-17665, Sterilization of health care products — Moist heat — Part 1: Requirements for 765 
the development, validation and routine control of a sterilization process for medical devices 766 
in The International Organization for Standardization. 2006: Geneva, Switzerland. 767 
50 768 
V. C. Abraham, D. L. Taylor, J. R. Haskins, Trends Biotechnol. 2004, 22, 15. 769 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 185 770 
51 771 
ISO-11137-2, Sterilization of health care products − Radiation − Part 2: Establishing the 772 
sterilization dose., in International Organization for Standardization. 2013: Geneva, 773 
Switzerland. 774 
52 775 
Microbiological Surveillance Program and Process Validation American Association of 776 
Tissue Banks, McLean, Virginia 2012. 777 
53 778 
Q. Q. Qiu, W. Q. Sun, J. Connor, Comprehensive Biomaterials (Ed.: P. Ducheyne), Elsevier, 779 
Amsterdam, The Netherlands 2011, p. 127. 780 
CrossRef 781 
54 782 
A. Dziedzic-Goclawska, A. Kaminski, I. Uhrynowska-Tyszkiewicz, W. Stachowicz, Cell 783 
Tissue Bank 2005, 6, 201. 784 
CrossRef | PubMed | CAS 785 
55 786 
C. R. Balsly, A. T. Cotter, L. A. Williams, B. D. Gaskins, M. A. Moore, L. Wolfinbarger, Jr., 787 
Cell Tissue Bank 2008, 9, 289. 788 
CrossRef | PubMed | Web of Science® Times Cited: 49 789 
56 790 
R. Singh, P. Gupta, P. Kumar, A. Kumar, M. P. Chacharkar, Cell Tissue Bank 2003, 4, 95. 791 
CrossRef | PubMed 792 
57 793 
N. Marsit, S. Dwejen, I. Saad, S. Abdalla, A. Shaab, S. Salem, E. Khanfas, A. Hasan, M. 794 
Mansur, M. Abdul Sammad, Cell Tissue Bank 2014, 15, 603. 795 
CrossRef | PubMed | Web of Science® Times Cited: 1 796 
58 797 
38 
 
Radiation sterilization of tissue allografts:requirements for validation and routine control: a 798 
code of practice, International Atomic Energy Agency, Vienna 2007. 799 
59 800 
S. Endres, M. Kratz, J. Musculoskelet Neuronal Interact 2009, 9, 25. 801 
PubMed | Web of Science® Times Cited: 5 802 
60 803 
B. E. Butterworth, J. R. Chapman, Regul. Toxicol. Pharmacol. 2007, 49, 149. 804 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 2 805 
61 806 
D. W. Jackson, G. E. Windler, T. M. Simon, Am. J. Sports Med. 1990, 18, 1. 807 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 194 808 
62 809 
A. White, D. Burns, T. W. Christensen, J. Biotechnol. 2006, 123, 504. 810 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 74 811 
63 812 
E. Shieh, A. Paszczynski, C. M. Wai, Q. Lang, R. L. Crawford, J. Microbiol. Methods 2009, 813 
76, 247. 814 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 18 815 
64 816 
W. A. Rutala, D. J. Weber, Am. J. Infect. Control 2013, 41, S2. 817 
CrossRef | PubMed | Web of Science® Times Cited: 18 818 
65 819 
A. Simmons, Sterilization of Biomaterials and Medical Devices. (Eds.: S. Lerouge, A. 820 
Simmone), Woodhead Publishing Limited, Cambridge, UK 2012, p. 310. 821 
CrossRef 822 
66 823 
M. Perrut, J. Supercrit Fluids 2012, 66, 359. 824 
CrossRef | CAS | Web of Science® Times Cited: 21 825 
67 826 
M. S. a. H. P. P. Wutzler, J. Clin. Microbiol. 1975, 1, 246. 827 
PubMed | Web of Science® Times Cited: 1 828 
68 829 
C. S. Frauke von Versen-Ḧoynck, S. Bachmann, D. E. M̈oller, Cell Tissue Bank 2004a, 5, 45. 830 
CrossRef 831 
39 
 
69 832 
P. D. Kemp, Peracetic Acid Sterilization of Collagen or Collagenous Tissue (Ed.: U. S. 833 
Patent), Organogenesis Inc., Canton, Mass, USA 1995. 834 
70 835 
A. Pruss, C. Perka, P. Degenhardt, U. Maronna, K. Buttner-Janz, B. Paul, K. Muller, C. 836 
Klumpp, J. C. Bruck, R. Von Versen, Cell Tissue Bank 2002, 3, 235. 837 
CrossRef | PubMed | CAS 838 
71 839 
W. A. Rutala, D. J. Weber, Am. J. Infect. Control 2013, 41, S2. 840 
CrossRef | PubMed | Web of Science® Times Cited: 18 841 
72 842 
S. Killeen, M. McCourt, Surgery 2012, 30, 687. 843 
73 844 
W. A. Rutala, D. J. Weber, J. Hosp. Infect. 1999, 43, S43. 845 
CrossRef | PubMed | Web of Science® Times Cited: 55 846 
74 847 
K. Shimizu, H. Yano, E. Nakamura, N. Kaku, Ann. Transplant. 2001, 6, 26. 848 
PubMed 849 
75 850 
M. N. Bathina, S. Mickelsen, C. Brooks, J. Jaramillo, T. Hepton, F. M. Kusumoto, J. Am. 851 
Coll. Cardiol. 1998, 32, 1384. 852 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 20 853 
76 854 
S. D. Ferreira, W. S. Dernell, B. E. Powers, R. A. Schochet, C. A. Kuntz, S. J. Withrow, R. M. 855 
Wilkins, Clin. Orthop. Relat. Res. 2001, 388, 233. 856 
CrossRef 857 
77 858 
Y. Ikarashi, T. Tsuchiya, A. Nakamura, Biomaterials 1995, 16, 177. 859 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 20 860 
78 861 
G. Fridman, G. Friedman, A. Gutsol, A. B. Shekhter, V. N. Vasilets, A. Fridman, Plasma 862 
Process Polym. 2008, 5, 503. 863 
Wiley Online Library | CAS | Web of Science® Times Cited: 722 864 
79 865 
40 
 
J. Heinlin, G. Morfill, M. Landthaler, W. Stolz, G. Isbary, J. L. Zimmermann, T. Shimizu, S. 866 
Karrer, J. Dtsch. Dermatol. Ges. 2010, 8, 968. 867 
PubMed | Web of Science® Times Cited: 85 868 
80 869 
M. Moreau, N. Orange, M. G. Feuilloley, Biotechnol. Adv. 2008, 26, 610. 870 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 190 871 
81 872 
M. G. Kong, G. Kroesen, G. Morfill, T. Nosenko, T. Shimizu, J. van Dijk, J. L. Zimmermann, 873 
New J. Phys. 2009, 11, 115012. 874 
CrossRef | Web of Science® Times Cited: 587 | ADS 875 
82 876 
C. Cheng, L. Peng, X. Lei, Z. Li-Ye, Z. Ru-J., Chin. Phys. 2006, 15, 1544. 877 
CrossRef | CAS | Web of Science® Times Cited: 30 | ADS 878 
83 879 
O. Schlüter, J. Ehlbeck, C. Hertel, M. Habermeyer, A. Roth, K. H. Engel, T. Holzhauser, D. 880 
Knorr, G. Eisenbrand, Mol. Nutr. Food Res. 2013, 57, 920. 881 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 25 882 
84 883 
B. Haertel, T. von Woedtke, K.-D. Weltmann, U. Lindequist, Biomol. Ther. 2014, 22, 477. 884 
CrossRef | CAS | Web of Science® Times Cited: 32 885 
85 886 
R. Morent, N. De Geyter, Biomedical Engineering − Frontiers and Challenges (Ed.: R. Fazel), 887 
In Tech, Rijeka, Croatia 2011, p. 25. 888 
86 889 
L. Bárdos, H. Baránková, Vacuum 2008, 83, 522. 890 
CrossRef | CAS | Web of Science® Times Cited: 16 | ADS 891 
87 892 
K. P. Arjunan, V. K. Sharma, S. Ptasinska, Int. J. Mol. Sci. 2015, 16, 2971. 893 
CrossRef | PubMed | Web of Science® Times Cited: 11 894 
88 895 
M. Y. Alkawareek, S. P. Gorman, W. G. Graham, B. F. Gilmore, Int. J. Antimicrob. Agents 896 
2014, 43, 154. 897 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 17 898 
89 899 
41 
 
S. A. Ermolaeva, A. F. Varfolomeev, M. Y. Chernukha, D. S. Yurov, M. M. Vasiliev, A. A. 900 
Kaminskaya, M. M. Moisenovich, J. M. Romanova, A. N. Murashev, I. I. Selezneva, T. 901 
Shimizu, E. V. Sysolyatina, I. A. Shaginyan, O. F. Petrov, E. I. Mayevsky, V. E. Fortov, G. E. 902 
Morfill, B. S. Naroditsky, A. L. Gintsburg, J. Med. Microbiol. 2011, 60, 75. 903 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 86 904 
90 905 
G. Fridman, G. Friedman, A. Gutsol, A. B. Shekhter, V. N. Vasilets, A. Fridman, Plasma 906 
Process Polym. 2008, 5, 503. 907 
Wiley Online Library | CAS | Web of Science® Times Cited: 722 908 
91 909 
X. Han, W. A. Cantrell, E. E. Escobara, S. Ptasinskab, Eur. Phys. J. D 2014, 68, 46. 910 
CrossRef | CAS | Web of Science® Times Cited: 7 | ADS 911 
92 912 
C. Sadiqali, M. Černák, M. Pavel, H. Josef, J. Appl. Biomed. 2010, 8, 55. 913 
CrossRef | CAS | Web of Science® Times Cited: 39 914 
93 915 
S. Emmert, F. Brehmer, H. Hänßle, A. Helmke, N. Mertens, R. Ahmed, D. Simon, D. 916 
Wandke, W. Maus-Friedrichs, G. Däschlein, M. P. Schön, W. Viöl, Clin. Plasma Med. 2013, 917 
1, 24. 918 
CrossRef 919 
94 920 
G. Daeschlein, S. Scholz, R. Ahmed, T. von Woedtke, H. Haase, M. Niggemeier, E. Kindel, 921 
R. Brandenburg, K. D. Weltmann, M. Juenger, J. Hosp. Infect. 2012, 81, 177. 922 
CrossRef | PubMed | Web of Science® Times Cited: 38 923 
95 924 
A. S. Wu, S. Kalghatgi, D. Dobrynin, R. Sensenig, E. Cerchar, E. Podolsky, E. Dulaimi, M. 925 
Paff, K. Wasko, K. P. Arjunan, K. Garcia, G. Fridman, M. Balasubramanian, R. Ownbey, K. 926 
A. Barbee, A. Fridman, G. Friedman, S. G. Joshi, A. D. Brooks, J. Surg. Res. 2013, 179, e1. 927 
CrossRef | PubMed | Web of Science® Times Cited: 18 928 
96 929 
B. Yang, J. Chen, Q. Yu, H. Li, M. Lin, A. Mustapha, L. Hong, Y. Wang, J. Dent. 2011, 39, 930 
48. 931 
CrossRef | PubMed | Web of Science® Times Cited: 33 932 
97 933 
42 
 
X. Zhou, Z. Xiong, Y. Cao, X. Lu, D. Liu, IEEE Trans. Plasma Sci. 2010, 38, 3370. 934 
CrossRef | Web of Science® Times Cited: 14 | ADS 935 
98 936 
N. O'Connor, O. Cahill, S. Daniels, S. Galvin, H. Humphreys, J. Hosp. Infect. 2014, 88, 59. 937 
CrossRef | PubMed | Web of Science® Times Cited: 17 938 
99 939 
M. R. Boscariol, A. J. Moreira, R. D. Mansano, I. S. Kikuchi, T. J. Pinto, Int. J. Pharm. 2008, 940 
353, 170. 941 
PubMed | Web of Science® Times Cited: 11 942 
100 943 
E. Curran, R. Duffy, D. Peretz, S. Park, B. Seiber, R. Smalley, A. Raghavan, M. Gurjar, D. 944 
Dobrynin, K. Wasko, A. Fridman, G. Fridman, D. Paog, Plasma Med. 2013, 3, 153. 945 
CrossRef 946 
101 947 
G. Avramidis, B. Stüwe, R. Wascher, M. Bellmann, S. Wieneke, A. von Tiedemann, W. Viöl, 948 
Surf. Coat. Technol. 2010, 205, S405. 949 
CrossRef | CAS | Web of Science® Times Cited: 7 950 
102 951 
S. Ptasinska, B. Bahnev, A. Stypczynska, M. Bowden, N. J. Mason, N. S. Braithwaite, Phys. 952 
Chem. Chem. Phys. 2010, 12, 7779. 953 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 27 954 
103 955 
E. Stoffels, Y. Sakiyama, D. B. Graves, Plasma Sci. IEEE Trans. 2008, 36, 1441. 956 
CrossRef | CAS | Web of Science® Times Cited: 182 | ADS 957 
104 958 
D. A. Mendis, M. Rosenberg, F. Azam, IEEE Trans. Plasma Sci. 2000, 28, 1304. 959 
CrossRef | Web of Science® Times Cited: 90 | ADS 960 
105 961 
J. L. Zimmermann, T. Shimizu, H. U. Schmidt, Y. F. Li, G. E. Morfill, G. Isbary, New J. 962 
Phys. 2012, 14, 073037. 963 
CrossRef | Web of Science® Times Cited: 17 | ADS 964 
106 965 
M. Laroussi, F. Leipold, Int. J. Mass Spectrom. 2004, 233, 81. 966 
CrossRef | CAS | Web of Science® Times Cited: 324 | ADS 967 
43 
 
107 968 
M. Laroussi, Plasma Process Polym. 2005, 2, 391. 969 
Wiley Online Library | CAS | Web of Science® Times Cited: 492 970 
108 971 
M. L. Burts, I. Alexeff, E. T. Meek, J. A. McCullers, Am. J. Infect. Control 2009, 37, 729. 972 
CrossRef | PubMed | Web of Science® Times Cited: 21 973 
109 974 
E. Kvam, B. Davis, F. Mondello, A. L. Garner, Antimicrob. Agents Chemother. 2012, 56, 975 
2028. 976 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 39 977 
110 978 
T. Maisch, T. Shimizu, Y. F. Li, J. Heinlin, S. Karrer, G. Morfill, J. L. Zimmermann, PLoS 979 
ONE 2012, 7, e34610. 980 
CrossRef | PubMed | Web of Science® Times Cited: 47 | ADS 981 
111 982 
T. Maisch, T. Shimizu, A. Mitra, J. Heinlin, S. Karrer, Y. F. Li, G. Morfill, J. L. 983 
Zimmermann, J. Ind. Microbiol. Biotechnol. 2012, 39, 1367. 984 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 13 985 
112 986 
C. M. Edelblute, M. A. Malik, L. C. Heller, Bioelectrochemistry 2015, 103, 22. 987 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 4 988 
113 989 
M. Korachi, C. Gurol, N. Aslan, J. Electrostat. 2010, 68, 508. 990 
CrossRef | CAS | Web of Science® Times Cited: 20 991 
114 992 
A. Fernandez, N. Shearer, D. R. Wilson, A. Thompson, Int. J. Food. Microbiol. 2012, 152, 993 
175. 994 
CrossRef | PubMed | Web of Science® Times Cited: 25 995 
115 996 
J. J. Cotter, P. Maguire, F. Soberon, S. Daniels, J. P. O'Gara, E. Casey, J. Hosp. Infect. 2011, 997 
78, 204. 998 
CrossRef | PubMed | Web of Science® Times Cited: 19 999 
116 1000 
44 
 
C. Wei, H. Jun, D. Ning, L. Xiao-Di, L. Guo-Hua, W. Xing-Quan, Z. Guo-Ping, G. Li-Hong, 1001 
Y. Si-Ze, Chin. Phys. Lett. 2012, 29, 075203. 1002 
CrossRef | CAS | Web of Science® Times Cited: 3 | ADS 1003 
117 1004 
R. Matthes, C. Bender, R. Schluter, I. Koban, R. Bussiahn, S. Reuter, J. Lademann, K. D. 1005 
Weltmann, A. Kramer, PLoS ONE 2013, 8, e70462. 1006 
CrossRef | PubMed | Web of Science® Times Cited: 15 | ADS 1007 
118 1008 
O. Lademann, A. Kramer, H. Richter, A. Patzelt, M. Meinke, J. Roewert-Huber, V. Czaika, K. 1009 
Weltmann, B. Hartmann, S. Koch, Laser Phys. Lett. 2011, 8, 313. 1010 
Wiley Online Library | Web of Science® Times Cited: 19 1011 
119 1012 
O. Lademann, A. Kramer, H. Richter, A. Patzelt, M. Meinke, V. Czaika, K. -D. Weltmann, B. 1013 
Hartmann, S. Koch, Skin Pharmacol. Physiol. 2011, 24, 284. 1014 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 26 1015 
120 1016 
A. Ali, Y. H. Kim, J. Y. Lee, S. Lee, H. S. Uhm, G. Cho, B. J. Park, E. H. Choi, Curr. Appl. 1017 
Phys. 2014, 14, S142. 1018 
CrossRef | Web of Science® Times Cited: 1 1019 
121 1020 
Y. F. Hong, J. G. Kang, H. Y. Lee, H. S. Uhm, E. Moon, Y. H. Park, Lett. Appl. Microbiol. 1021 
2009, 48, 33. 1022 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 44 1023 
122 1024 
S. Shimizu, S. Barczyk, P. Rettberg, T. Shimizu, T. Klaempfl, J. L. Zimmermann, T. 1025 
Hoeschen, C. Linsmeier, P. Weber, G. E. Morfill, H. M. Thomas, Plant. Space Sci. 2014, 90, 1026 
60. 1027 
CrossRef | Web of Science® Times Cited: 7 | ADS 1028 
123 1029 
J. Jeon, T. Klaempfl, J. Zimmermann, G. Morfill, T. Shimizu, New J. Phys. 2014, 16, 103007. 1030 
CrossRef | Web of Science® Times Cited: 2 | ADS 1031 
124 1032 
S. Patil, T. Moiseev, N. N. Misra, P. J. Cullen, J. P. Mosnier, K. M. Keener, P. Bourke, J. 1033 
Hosp. Infect. 2014, 88, 162. 1034 
45 
 
CrossRef | PubMed | Web of Science® Times Cited: 10 1035 
125 1036 
F. Rossi, O. Kylián, Sterilisation of Biomaterials and Medical Devices (Eds.: S. Lerouge, A. 1037 
Simmons), Woodhead Publishing Series in Biomaterials, Philadelphia, USA 2012, p. 117. 1038 
CrossRef 1039 
126 1040 
H. Shintani, Biocontrol. Sci. 2016, 21, 63. 1041 
CrossRef | PubMed | Web of Science® 1042 
127 1043 
B. J. Park, K. Takatori, M. H. Lee, D. -W. Han, Y. I. Woo, H. J. Son, J. K. Kim, K.-H. Chung, 1044 
S. O. Hyun, J.-C. Park, Surf. Coat. Technol. 2007, 201, 5738. 1045 
CrossRef | CAS | Web of Science® Times Cited: 29 1046 
128 1047 
D. L. Bayliss, J. L. Walsh, G. Shama, F. Iza, M. G. Kong, New J. Phys. 2009, 11, 115024. 1048 
CrossRef | Web of Science® Times Cited: 26 | ADS 1049 
129 1050 
J. Julák, O. Janoušková, V. Scholtz, K. Holada, Plasma Process Polym. 2011, 8, 316. 1051 
Wiley Online Library | CAS | Web of Science® Times Cited: 17 1052 
130 1053 
A. Holmberg, R. Lood, M Mörgelin, B. Söderquist, E. Holst, M. Collin, B. Christensson, M. 1054 
Rasmussen, Clin. Microbiol. Infect. 2009, 15, 787. 1055 
Wiley Online Library | PubMed | Web of Science® Times Cited: 53 1056 
131 1057 
T. Maisch, T. Shimizu, G. Isbary, J. Heinlin, S. Karrer, T. G. Klampfl, Y. F. Li, G. Morfill, J. 1058 
L. Zimmermann, Appl. Environ. Microbiol. 2012, 78, 4242. 1059 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 31 1060 
132 1061 
K. Fricke, I. Koban, H. Tresp, L. Jablonowski, K. Schroder, A. Kramer, K. D. Weltmann, T. 1062 
von Woedtke, T. Kocher, PLoS ONE 2012, 7, e42539. 1063 
CrossRef | PubMed | Web of Science® Times Cited: 35 | ADS 1064 
133 1065 
H. Yasuda, T. Miura, H. Kurita, K. Takashima, A. Mizuno, Plasma Process Polym. 2010, 7, 1066 
301. 1067 
Wiley Online Library | CAS | Web of Science® Times Cited: 45 1068 
46 
 
134 1069 
A. Mai-Prochnow, A. B. Murphy, K. M. McLean, M. G. Kong, K. K. Ostrikov, Int. J. 1070 
Antimicrob. Agents 2014, 43, 508. 1071 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 35 1072 
135 1073 
S. Bekeschus, A. Schmidt, K.-D. Weltmann, T. von Woedtke, Clin. Plasma Med. 2016, 4, 19. 1074 
CrossRef 1075 
136 1076 
F. Brehmer, H. A. Haenssle, G. Daeschlein, R. Ahmed, S. Pfeiffer, A. Gorlitz, D. Simon, M. 1077 
P. Schon, D. Wandke, S. Emmert, J. Eur. Acad. Dermatol. Venereol. 2015, 29, 148. 1078 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 20 1079 
137 1080 
E. Stoffels, I. E. Kieft, R. E. J. Sladek, J. Phys. D Appl. Phys. 2003, 36, 2908. 1081 
CrossRef | CAS | Web of Science® Times Cited: 136 | ADS 1082 
138 1083 
T Jiang, H. Zhao, C. Wang, G. Rao, A. Li, H. Tolner, B. Li, Plasma Med. 2012, 2, 179. 1084 
CrossRef 1085 
139 1086 
E. Stoffels, A. J. Flikweert, W. W. Stoffels, G. M. W. Kroesen, Plasma Sources Sci. Technol. 1087 
2002, 11, 383. 1088 
CrossRef | CAS | Web of Science® Times Cited: 355 | ADS 1089 
140 1090 
C. Welz, S. Becker, Y.-F. Li, T. Shimizu, J. Jeon, S. Schwenk-Zieger, H. M. Thomas, G. 1091 
Isbary, G. E. Morfill, U. Harréus, J. Phys. D Appl. Phys. 2013, 46, 045401. 1092 
CrossRef | CAS | Web of Science® Times Cited: 10 | ADS 1093 
141 1094 
X. Pei, X. Lu, J. Liu, D. Liu, Y. Yang, K. Ostrikov, K. C. Paul, Y. Pan, J. Phys. D Appl. Phys. 1095 
2012, 45, 165205. 1096 
CrossRef | CAS | Web of Science® Times Cited: 44 | ADS 1097 
142 1098 
D. Dobrynin, G. Fridman, G. Friedman, A. Fridman, New J. Phys. 2009, 11, 115020. 1099 
CrossRef | ADS 1100 
143 1101 
A. H. Tehrani, P. Davari, S. Singh, A. Oloyede, J. Mater. Sci. Mater. Med. 2014, 25, 953. 1102 
47 
 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 3 1103 
144 1104 
E. J. Szili, J. W. Bradley, R. D. Short, J. Phys. D 2014, 47, 152002. 1105 
CrossRef | CAS | Web of Science® Times Cited: 22 | ADS 1106 
145 1107 
D. Dobrynin, G. Fridman, G. Friedman, A. A. Fridman, Plasma Med. 2012, 2, 71. 1108 
CrossRef 1109 
146 1110 
C. X. Wang, Y. Liu, H. L. Xu, Y. Ren, Y. P. Qiu, Appl. Surf. Sci. 2008, 254, 2499. 1111 
CrossRef | CAS | Web of Science® Times Cited: 51 | ADS 1112 
147 1113 
C. X. Wang, Y. P. Qiu, Surf. Coat. Technol. 2007, 201, 6273. 1114 
CrossRef | CAS | Web of Science® Times Cited: 69 1115 
148 1116 
K. Heuer, M. A. Hoffmanns, E. Demir, S. Baldus, C. M. Volkmar, M. Rohle, P. C. Fuchs, P. 1117 
Awakowicz, C. V. Suschek, C. Oplander, Nitric Oxide 2015, 44, 52. 1118 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 13 1119 
149 1120 
F. von Versen-Hoeynck, A. P. Steinfeld, J. Becker, M. Hermel, W. Rath, U. Hesselbarth, 1121 
Biologicals 2008, 36, 248. 1122 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 17 1123 
150 1124 
E. Noriega, G. Shama, A. Laca, M. Díaz, M. G. Kong, Food Microbiol. 2011, 28, 1293. 1125 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 59 1126 
151 1127 
S. S. Ab Hamid, N. K. Zahari, N. Yusof, A. Hassan, Cell Tissue Bank 2014, 15, 15. 1128 
CrossRef | PubMed | Web of Science® Times Cited: 5 1129 
152 1130 
Z. Nor Kamilia, Y. N. Suzina SAH, Regen. Res. 2014, 3, 64. 1131 
153 1132 
R. Singh, M. P. Chacharkar, J. Tissue Viability 2011, 20, 49. 1133 
CrossRef | PubMed | Web of Science® Times Cited: 7 1134 
154 1135 
S. Kitazaki, A. Tanaka, N. Hayashi, Vacuum 2014, 110, 217. 1136 
48 
 
CrossRef | CAS | Web of Science® Times Cited: 5 | ADS 1137 
155 1138 
M. Annunziata, L. Canullo, G. Donnarumma, P. Caputo, L. Nastri, L. Guida, Med. Oral Patol. 1139 
Oral Cir. Bucal 2016, 21, e118. 1140 
CrossRef | PubMed | Web of Science® Times Cited: 1 1141 
156 1142 
E. Simoncelli, D. Barbieri, R. Laurita, A. Liguori, A. Stancampiano, L. Viola, R. Tonini, M. 1143 
Gherardi, V. Colombo, Clin. Plasma Med. 2015, 3, 77. 1144 
CrossRef 1145 
157 1146 
C.-W. Kan, C.-F. Lam, C.-K. Chan, S.-P. Ng, Carbohydr. Polym. 2014, 102, 167. 1147 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 10 1148 
158 1149 
L. Bárdos, H. Baránková, Thin Solid Films 2010, 518, 6705. 1150 
CrossRef | CAS | Web of Science® Times Cited: 85 | ADS 1151 
159 1152 
C. Wang, Y. Qiu, Surf. Coat. Technol. 2007, 201, 6273. 1153 
CrossRef | CAS | Web of Science® Times Cited: 69 1154 
160 1155 
S. Lerouge, M. R. Wertheimer, L. Yahia, Plasmas Polym. 2001, 6, 175. 1156 
CrossRef | CAS 1157 
161 1158 
E. Stoffels, I. E. Kieft, R. E. J. Sladek, L. J. M. v. d. Bedem, E. P. v. d. Laan, M. Steinbu, 1159 
Plasma Sources Sci. Technol. 2006, 15, S169. 1160 
CrossRef | CAS | Web of Science® Times Cited: 173 | ADS 1161 
162 1162 
N. De Geyter, R. Morent, Annu. Rev. Biomed. Eng. 2012, 14, 255. 1163 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 26 1164 
163 1165 
S. Pankaj, N. Misra, P. Cullen, Innov. Food Sci. Emerg. Technol. 2013, 19, 153. 1166 
CrossRef | CAS | Web of Science® Times Cited: 29 1167 
164 1168 
H. Eto, Y. Ono, A. Ogino, M. Nagatsu, Appl. Phys. Lett. 2008, 93, 221502. 1169 
CrossRef | CAS | Web of Science® Times Cited: 36 | ADS 1170 
49 
 
165 1171 
T. Lee, P. Puligundla, C. Mok, Food Control 2015, 51, 149. 1172 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 7 1173 
166 1174 
H. I. Yong, H. -J. Kim, S. Park, A. U. Alahakoon, K. Kim, W. Choe, C. Jo, Food Microbiol. 1175 
2015, 46, 46. 1176 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 14 1177 
167 1178 
O. V. Penkov, M. Khadem, W. -S. Lim, D. -E. Kim, J. Coat. Technol. Res. 2015, 12, 225. 1179 
CrossRef | CAS | Web of Science® Times Cited: 8 1180 
168 1181 
C. Wiegand, M. Abel, P. Ruth, T. Wilhelms, D. Schulze, J. Norgauer, U. -C. Hipler, J. 1182 
Biomed. Mater. Res. B Appl. Biomater. 2009, 90, 710. 1183 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 21 1184 
169 1185 
E. Y. Elenes, S. A. Hunter, J. Bone Joint Surg. Am. 2014, 96, 1321. 1186 
CrossRef | PubMed | Web of Science® Times Cited: 3 1187 
170 1188 
C. M. Deeley, Radiat. Phys. Chem. 2004, 71, 505. 1189 
CrossRef | CAS | Web of Science® Times Cited: 1 | ADS 1190 
171 1191 
D. Cheung, N. Perelman, D. Tong, M. Nimni, J. Biomed. Mater. Res. 1990, 24, 581. 1192 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 95 1193 
172 1194 
S. Baloda, J. Martin, J. Carter, E. Jenness, B. Judd, K. Smeltz, I. Uettwiller, M. Hockstad, 1195 
Guide to irradiation and sterilization of single-use bioprocess components and systems. The 1196 
Society of the Plastics Industry, Inc. The irradiation and sterilization subcommittee of the 1197 
bioprocess systems alliance, 2008, 2, 10. 1198 
173 1199 
A. Hoburg, S. Keshlaf, T. Schmidt, M. Smith, U. Gohs, C. Perka, A. Pruss, S. Scheffler, Cell 1200 
Tissue Bank 2014, 16, 219. 1201 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 2 1202 
174 1203 
M. Smith, R. Galloway, Radiat. Phys. Chem. 2004, 71, 531. 1204 
50 
 
CrossRef | CAS | Web of Science® | ADS 1205 
175 1206 
G. da Cunha Mendez, T. da Silva Brandao, C. Miranda Silva, Expert Rev. Med. Devices 1207 
2008, 5, 323. 1208 
CrossRef | PubMed | CAS 1209 
176 1210 
G. C. Mendes, T. R. Brandao, C. L. Silva, Am. J. Infect. Control 2007, 35, 574. 1211 
CrossRef | PubMed | Web of Science® Times Cited: 66 1212 
177 1213 
T. M. Moore, E. Gendler, J. Orthop. Res. 2004, 22, 1358. 1214 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 10 1215 
178 1216 
A. Nather, J. L. L. Chew, Z. Aziz, Radiation in Tissue Banking − Basic Science and Clinical 1217 
Applications of Irradiated Tissue Allografts (Eds.: A. Nather, N. Yusof, N. Hilmy), © World 1218 
Scientific Publishing Co. Pte. Ltd., Singapore 2007. 1219 
CrossRef 1220 
179 1221 
ISO-10993-7, Biological evaluation of medical devices − Part 7: Ethylene oxide sterilization 1222 
residuals., in The International Organization for Standardization. 2008: Geneva, Swetzerland. 1223 
180 1224 
T. S. Roberts, D. Drez, Jr., W. McCarthy, R. Paine, Am. J. Sports Med. 1991, 19, 35. 1225 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 109 1226 
181 1227 
Ethylene Oxide (EtO): Evidence of Carcinogenicity, U.S. Department of Health and Human 1228 
Services, National Institute for Occupational Safety and Health, USA 1981. 1229 
182 1230 
K. Steenland, E. Whelan, J. Deddens, L. Stayner, E. Ward, Cancer Causes Control 2003, 14, 1231 
531. 1232 
CrossRef | PubMed | Web of Science® Times Cited: 23 1233 
183 1234 
V. M. Steelman, AORN J. 1992, 55, 773. 1235 
CrossRef | PubMed | CAS 1236 
184 1237 
51 
 
Preventing worker injuries and deaths from explosions in industrial ethylene oxide 1238 
sterilization facilities, Public Health Service, Centers for Disease Control and Prevention, 1239 
National Institute for Occupational Safety and Health, Atlanta, GA 2007. 1240 
185 1241 
C. T. Vangsness, Jr., P. P. Wagner, T. M. Moore, M. R. Roberts, Arthroscopy 2006, 22, 1351. 1242 
CrossRef | PubMed | Web of Science® Times Cited: 32 1243 
186 1244 
Y. C. Chien, H. H. Liu, Y. C. Lin, P. C. Su, L. H. Li, C. P. Chang, D. T. Tang, C. Y. Chen, J. 1245 
Biomed. Mater. Res. B Appl. Biomater. 2007, 83, 527. 1246 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 8 1247 
187 1248 
B. J. Park, K. Takatori, M. H. Lee, D.-W. Han, Y. I. Woo, H. J. Son, J. K. Kim, K.-H. Chung, 1249 
S. O. Hyun, J. -C. Park, Surf. Coat. Technol. 2007, 201, 5738. 1250 
CrossRef | CAS | Web of Science® Times Cited: 29 1251 
188 1252 
B. A. Niemira, J. Food Sci. 2012, 77, M171. 1253 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 29 1254 
189 1255 
A. Blumhagen, P. Singh, A. Mustapha, M. Chen, Y. Wang, Q. Yu, Am. J. Dent. 2014, 27, 84. 1256 
PubMed | Web of Science® Times Cited: 3 1257 
190 1258 
P. Sun, Y Sun, H. Wu, W. Zhu, J. L. Lopez, W. Liu, J. Zhang, R. Li, J. Fang, Appl. Phys. 1259 
Lett. 2011, 98, 021501. 1260 
CrossRef | CAS | Web of Science® Times Cited: 29 | ADS 1261 
191 1262 
B. Dasan, M. Mutlu, I. Boyaci, Int. J. Food Microbiol. 2016, 216, 50. 1263 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 3 1264 
192 1265 
M. Selcuk, L. Oksuz, P. Basaran, Bioresour. Technol. 2008, 99, 5104. 1266 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 80 1267 
193 1268 
N. S. Panikov, S. Paduraru, R. Crowe, P. J. Ricatto, C. Christodoulatos, K. Becker, IEEE 1269 
Trans. Plasma Sci. 2002, 30, 1424. 1270 
CrossRef | Web of Science® Times Cited: 43 | ADS 1271 
52 
 
194 1272 
R. A. Venezia, M. Orrico, E. Houston, S. M. Yin, Y. Y. Naumova, Infect. Contol Hosp. 1273 
Epidemiol. 2008, 29, 430. 1274 
CrossRef | PubMed | Web of Science® Times Cited: 35 1275 
195 1276 
N. Alshraiedeh, M. Alkawareek, S. Gorman, W. Graham, B. Gilmore, J. Appl. Microbiol. 1277 
2013, 115, 1420. 1278 
Wiley Online Library | PubMed | CAS | Web of Science® Times Cited: 12 1279 
196 1280 
O. Terrier, B. Essere, M. Yver, M. Barthélémy, M. Bouscambert-Duchamp, P. Kurtz, D. 1281 
VanMechelen, F. Morfin, G. Billaud, O. Ferraris, J. Clin. Virol. 2009, 45, 119. 1282 
CrossRef | PubMed | CAS | Web of Science® Times Cited: 22 1283 
197 1284 
D. Ziuzina, L. Han, P. J. Cullen, P. Bourke, Int. J. Food Microbiol. 2015, 210, 53. 1285 
CrossRef | PubMed | Web of Science® Times Cited: 5 1286 
198 1287 
M. Moisan, P. Levif, J. Séguin, J. Barbeau, J. Phys. D Appl. Phys. 2014, 47, 285404. 1288 
CrossRef | CAS | Web of Science® Times Cited: 1 | ADS 1289 
199 1290 
Q. Y. Nie, Z. Cao, C. S. Ren, D. Z. Wang, M. G. Kong, New J. Phys. 2009, 11, 115015. 1291 
CrossRef | Web of Science® Times Cited: 44 | ADS 1292 
200 1293 
A. N. Aleynik, A. N. Baykov, M. B. Baskakov, G. T. Dambaev, O. I. Deneko, E. P. 1294 
Krasnozhenov, E. V. Semichev, O. S. Zhdanova, Strategic Technology (IFOST), 2012 7th 1295 
International Forum, Tomsk Polytechnic University, Russia 2012. 1296 
Related content 1297 
 1298 
